TLRY Earnings: EBITDA Growth Still Needs Cash Proof
Tilray Brands’ TLRY fiscal 2026 earnings frame the central question for cannabis equities more clearly than the latest broad tape move: can reported operating improvement become durable per-share cash generation? The company delivered $915.454 million in net revenue and $61.139 million in adjusted EBITDA for the fiscal year ended May 31, 2026, then guided to $68 million to $75 million of adjusted EBITDA for fiscal 2027. But it also reported negative free cash flow of $98.624 million. That divergence—not the headline EBITDA trajectory—is the analytical fulcrum.
For U.S.-focused cannabis investors, Tilray is not a pure-play read-through for domestic multi-state operators. Its cannabis, distribution and beverage exposure create a more international and diversified operating mix than CURLF, CRLBF, TSNDF, AAWH, or GRWG. Yet the filing remains highly relevant to the U.S. cannabis equity complex because it addresses the same market-wide issues: constrained capital, the cost of pursuing growth before federal policy clarity, dilution sensitivity, competition from illicit markets, and the difference between adjusted earnings measures and cash realized for equity holders.
The thesis is straightforward: TLRY’s fiscal 2027 guide supports an operational-growth narrative, but the equity-quality test is free-cash-flow conversion and per-share discipline. Until management demonstrates that higher adjusted EBITDA translates into lower cash burn without material dilution, the appropriate read-through is selective rather than sector-wide.
The filing establishes the earnings debate
In its fiscal 2026 earnings release filed as SEC Exhibit 99.1, Tilray reported $915.454 million of net revenue, $61.139 million of adjusted EBITDA and negative free cash flow of $98.624 million. The company stated that it expects more than $1 billion in annual revenue and issued fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million. The filing-led message is constructive at the operating level: management is setting out an earnings path above the prior year’s adjusted EBITDA result. But it is incomplete as an equity case without a credible bridge to cash generation.
That distinction matters because adjusted EBITDA is not free cash flow, and an earnings guide alone does not establish the value ultimately accruing to shareholders. The core primary-source disclosure is available in Tilray’s fiscal 2026 earnings release filed as SEC Exhibit 99.1.
A favorable fiscal 2027 outcome would be delivery within or above the stated $68 million to $75 million range while cash consumption improves meaningfully. The stronger outcome would include positive free cash flow without a material increase in shares outstanding. Conversely, a weaker outcome would be EBITDA delivery that remains disconnected from free cash flow, requiring additional equity issuance or leaving the company dependent on balance-sheet flexibility.
This is why the market should resist treating an EBITDA guide as a full earnings resolution. The guide is useful. It signals management’s operating ambition and establishes a measurable benchmark. But the absence of a disclosed reconciliation from fiscal 2027 adjusted EBITDA to GAAP operating income and free cash flow leaves the cash-conversion question open.
The balance sheet turns growth into a per-share question
The balance-sheet disclosure adds urgency to that question. At May 31, 2026, Tilray reported $225.977 million of cash and cash equivalents, $5.289 million of marketable securities, $8.775 million of bank indebtedness, $138.585 million of current and long-term debt, and $79.529 million of convertible debentures.
Equally important, shares issued and outstanding were 131,683,075, compared with 106,067,875 one year earlier after retrospective adjustment for the reverse split. That is the measure that makes the earnings story an equity story. Higher EBITDA can still fail to create stronger per-share economics if the capital structure expands faster than cash-flow capacity.
The company’s fiscal 2026 balance-sheet information appears alongside the earnings disclosure in the SEC-filed Exhibit 99.1. For positioning purposes, the key monitoring threshold is not merely whether TLRY reaches the lower end of its EBITDA range. It is whether the reported share count remains proportionate to the business’s future cash-generation capacity.
This concern is not unique to Tilray. Across U.S. cannabis operators and ancillaries, investors have repeatedly had to distinguish enterprise growth from equity value creation. CURLF rose 5.64% to $10.11 in the latest tape, while CRLBF gained 5.16% to $0.75, AAWH rose 5.97% to $0.55, and TSNDF advanced 5.17% to $0.66. Those moves point to a firmer session for several U.S.-exposed operators, but they do not eliminate the sector’s financing and policy dependencies.
The broader listed cannabis complex also saw MSOS rise 3.58% to $4.92, MSOX gain 5.00% to $2.94, and MJ advance 3.13% to $26.17. Such moves can amplify sentiment around federal-policy optionality, but they should not be confused with company-specific proof of cash conversion.
BrewDog is the global differentiator—and execution variable
Tilray’s global structure distinguishes its earnings setup from the U.S. MSO cohort. The company described BrewDog as a fiscal 2026 acquisition supporting a pro forma global beverage platform of approximately $500 million. An earlier fiscal third-quarter release described the acquisition price as approximately £40 million in cash and referenced a Carlsberg partnership beginning in 2027.
The BrewDog transaction matters because it expands the debate beyond U.S. cannabis reform. For TLRY, the earnings case rests on cannabis, distribution and beverage execution rather than a single jurisdictional regulatory outcome. That can diversify revenue sources, but it also makes integration, cost control and capital allocation central to the forecast.
The relevant primary-source filing is Tilray’s fiscal third-quarter earnings release. The non-U.S. angle is therefore not decorative: it is embedded in the company’s strategy. A beverage platform with international characteristics may provide operating breadth unavailable to a U.S.-only cannabis operator, but it also introduces an additional execution hurdle. Investors should require disclosed evidence that the beverage platform improves profitability or cash flow rather than simply increasing the revenue base.
That is a meaningful contrast with the U.S. MSO basket. CURLF, CRLBF, AAWH, and TSNDF remain more directly tethered to U.S. state-market performance and federal-policy expectations. Tilray carries those policy sensitivities too, but its investment debate is broader: whether diversification has created a scalable cash-generative platform or merely a larger, more complex operating perimeter.
Federal policy remains an option, not an earnings estimate
The U.S. marijuana-rescheduling process remains a material policy variable, but the disclosed procedural record does not establish final timing or a final outcome. The DEA hearing occurred from June 29 through July 15, 2026. The administrative law judge set August 17, 2026 as the deadline for proposed transcript corrections and post-hearing briefs.
That sequence is documented in the DEA order for transcript corrections and post-hearing briefs. It provides a concrete procedural marker, not a basis to model a definitive operating benefit today.
For U.S. cannabis equities, that distinction is critical. Rescheduling has the potential to alter the narrative around tax burdens, capital availability and institutional participation, but timing uncertainty means investors should not convert policy hope into near-term earnings assumptions. The latest market action illustrates the sensitivity: TLRY rose 2.99% to $4.14, while CRON gained 3.03% to $3.23 and OGI added 2.38% to $1.07. The tape supports renewed attention, but it does not resolve the regulatory timetable.
Tilray itself identifies substantial competition across both cannabis and beverage operations, including illicit-market participants and large, well-capitalized competitors, in its fiscal 2026 Form 10-K. That filing is an important counterweight to a policy-led narrative: even a more favorable regulatory setting does not automatically solve price competition, margin pressure or execution risk.
Forecast framework: what must happen next
The base operating forecast is management’s own: fiscal 2027 adjusted EBITDA of $68 million to $75 million, with annual revenue expected to exceed $1 billion. The analytical base case should be more demanding than simple guide attainment. It should require improving cash conversion and controlled share count.
The constructive scenario is EBITDA above $75 million, supported by execution across cannabis, international medical markets, distribution and beverage, with positive free cash flow and no material dilution. The base scenario is EBITDA within the guided range, with reduced cash consumption but without yet proving positive free cash flow. The downside scenario is EBITDA below $68 million, persistent negative free cash flow, and a rising share count.
Risk factors are explicit:
- Cash-flow risk: negative free cash flow of $98.624 million is the starting point, not a historical footnote.
- Dilution risk: the increase to 131,683,075 shares outstanding makes per-share monitoring indispensable.
- Integration risk: BrewDog must demonstrate profitability or cash-flow improvement rather than only platform scale.
- Competition risk: Tilray’s own 10-K identifies illicit-market and well-capitalized competitors across cannabis and beverage.
- Policy-timing risk: the DEA proceeding has a documented process history but no disclosed final decision.
Bottom line
TLRY has established a credible fiscal 2027 operating benchmark: more than $1 billion in expected annual revenue and $68 million to $75 million in adjusted EBITDA. The market’s task is now to separate earnings growth from shareholder-value creation. The decisive evidence will be free-cash-flow improvement, share-count discipline and quantified BrewDog execution.
What we’d watch: quarterly evidence that higher adjusted EBITDA is reducing cash burn, alongside movement in the 131,683,075 share count and disclosed profitability from the beverage platform. For U.S. cannabis exposure, we would lean toward treating rescheduling as an option value rather than an earnings input, while using TLRY, CURLF, CRLBF, AAWH, TSNDF, and GRWG as differentiated expressions of the same capital-discipline test.